Swiss pharmaceutical company Novartis is laying off more than one in ten employees in Switzerland over the next three years – 1,400 of 11,600 jobs will go. It also plans to cut 8,000 of 108,000 jobs worldwide.
This content was published on
2 minutes
Keystone-SDA/ts
Español
es
Novartis eliminará 1 400 puestos de trabajo en Suiza
On Tuesday the Basel-based company informed its employees in detail about the wave of redundancies for the first time. All sites are affected.
Novartis confirmed corresponding reports by TA-Media newspapers in response to an enquiry from news agency AWP.
At the beginning of April Novartis announced a comprehensive restructuring, which it hopes will result in savings of at least $1 billion (CHF960 million) by 2024. The centrepiece is the merger of the previously separate divisions Innovative Pharmaceuticals and Cancer Drugs.
In addition to adapting its operational structure, Novartis is also simplifying its global functions in finance, human resources, legal and communications. This will eliminate positions across the company, according to a spokesperson.
“Novartis is making rapid progress in implementing these changes across the organisation and has already completed the appointment of most leadership teams at the global level,” he said.
The spokesperson added that the company was aware of the impact of these changes on employees and was ensuring that all consultation requirements were met, through representative bodies where appropriate.
In Switzerland, formal consultations with employee representatives at the non-management level and consultations with management in the affected areas were already underway, he said.
More
More
Novartis: The making of a pharma giant
This content was published on
The company formed when Ciba Geigy and Sandoz merged and analysts say it’s a big success. The merger cost around 10,000 jobs but in the long-run more were created. The current CEO concedes that the merger also meant the loss of the Ciba corporate identity. Novartis’ profits shrank by a third in 2015, partly because…
What can be done to protect biodiversity in your country?
Swiss voters are set to decide on a people’s initiative calling for better protection of ecosystems in the country. Have your say on the September 22 vote.
Swiss investigate four people linked to Russian oligarch
This content was published on
The Office of the Attorney General of Switzerland is investigating four individuals linked to Russian oligarch Suleyman Kerimov.
Swiss government scrambles to deal with egg shortage
This content was published on
From September 1, more eggs intended for consumption may be imported into Switzerland. In allowing this, the government wants to secure the supply of eggs for consumers.
This content was published on
Agricultural research sees new development opportunities for Swiss sparkling wines in the face of declining wine consumption. In a survey, half of consumers expressed a willingness to pay more for local products than for foreign ones.
Locarno spotlights filmmakers from South America and Caribbean
This content was published on
The Open Doors section of the Locarno Film Festival has named the winners for 2024. The spotlight is on the South American and Caribbean regions.
Storm paralyses trains to popular Swiss tourist resort
This content was published on
The railway line between Zweilütschinen and Grindelwald in central Switzerland is expected to remain closed until Friday following heavy rains.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis to cut 2,200 Swiss jobs by 2020
This content was published on
Around 1,500 jobs are affected in production and 700 in services. Novartis currently employs 13,000 people across Switzerland.
This content was published on
Swiss pharmaceutical firm Novartis filed the most international trademark applications with the World Intellectual Property Organization (WIPO) .
Novartis pays big fine for bribing doctors in the US
This content was published on
Swiss pharma company Novartis will pay $729 million to US authorities in an out-of-court settlement over charges that the company bribed doctors to use its drugs.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.